Compare CDZI & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZI | VRXA |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | Switzerland |
| Employees | 31 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.2M | 390.3M |
| IPO Year | N/A | N/A |
| Metric | CDZI | VRXA |
|---|---|---|
| Price | $3.01 | $1.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 951.5K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.97 | N/A |
| Revenue Next Year | $102.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $1.70 |
| 52 Week High | $6.96 | $4.50 |
| Indicator | CDZI | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 29.98 |
| Support Level | N/A | $1.74 |
| Resistance Level | $5.08 | $2.29 |
| Average True Range (ATR) | 0.24 | 0.20 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 20.41 | 13.46 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, generating maximum revenue engaged in providing water filtration solutions for impaired or contaminated groundwater sources.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.